Coverage
4 companies
- Lead links
- 2
- Instruments
- Equity / unspecified
- Sourced relationships
- 4
- Distinct source URLs
- 7
- Crawl status
- Official page mapped
Sourced investor record
Sofinnova Partners
European life-sciences portfolio; UK filter required
Portfolio links42 lead relationships
- Indexing state
- Evidence-qualified
- Latest dated link
- 2024-10-01
- Earliest dated link
- 2023-01-01
- Snapshot
- 2026-08-25
Official source
Portfolio located
Open official portfolio ↗Evidence ledger
4 retained relationships
A link records a disclosed or retained research relationship; it does not imply a current holding. Every row exposes the source layer, observation date, match method and publication state. Exact dated matches link onward to the funding record.
Observed roles
Evidence threshold
This page meets the retained indexing threshold through an official portfolio URL, three or more linked companies or two distinct relationship-source URLs.
4 relationships shown
| Company | Role | Round | Date | Named sources | Match / state |
|---|---|---|---|---|---|
| Purespring Therapeutics | lead | Series B | 2024-10-01 | Globenewswire ↗ · Fiercebiotech ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Mission Therapeutics | lead | Series D | 2024-03-01 | Finsmes ↗ · Sofinnovapartners ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Sitryx Therapeutics | participant | Series B (described in source as 'additional financing' - letter not explicit) | 2023-09-01 | Svhealthinvestors ↗ · Globenewswire ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Crescendo Biologics | participant | Series C/D (letter unconfirmed) | 2023-01-01 | Cambridgeindependent ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
Recent linked companies
4 of 4 observed companies
The most recently dated retained relationships are shown first; the complete sourced set remains in the ledger above.